Navigation Links
JDRF to establish an autoimmunity center at University of Colorado Denver

AURORA, Colo. (Jan. 28, 2008) Researchers at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver have new resources in their fight against type 1 diabetes: The Juvenile Diabetes Research Foundation has approved funding for the establishment of a JDRF Autoimmunity Center at the Barbara Davis Center for Childhood Diabetes, only the seventh in the nation. The Autoimmunity Center will receive approximately $1 million a year over the next five years to further fund research leading to a cure for type 1 diabetes.

The goal of this partnership is to utilize the Barbara Davis Centers resources in collaboration with JDRFs to create an Autoimmunity Center to develop therapies specifically aimed at immunoprevention of type 1 diabetes. Type 1 diabetes is an autoimmune disease that develops when the bodys immune system mistakenly targets the beta cells of the pancreas, the cells that make insulin.

The JDRF Center will bring together faculty with complementary expertise and knowledge to advance the understanding of pathogenesis diabetes in animals and humans as well as allow us to implement trials in human subjects based on the results, said John Hutton, PhD, research director at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver and principal investigator on the grant. We have learned an immense amount in the past 20 years about the causes of the disease and have sophisticated genetic and immunological assays to predict it -- the challenge is how to translate this knowledge into effective therapies, particularly those aimed at circumventing the progression of autoimmunity to clinical disease. The JDRF Center will help us tremendously with addressing this challenge.

We are delighted to establish the JDRF Autoimmunity Center at the Barbara Davis Center, said Teodora Staeva, Ph.D. Program Director, Autoimmunology, at JDRF. This JDRF Center will focus on developing novel antigen-specific approaches to predict, prevent, and possibly reverse type 1 diabetes.

The JDRF Center brings together a team of basic scientists and clinical researchers, and includes Dr. Hutton, along with George Eisenbarth, MD, PhD; Peter Gottlieb, MD; Howard Davidson, PhD; and Danny Zipris. The Barbara Davis Center for Childhood Diabetes will be the administrative hub of this JDRF Autoimmunity Center.

Two of the three main research projects will investigate the new autoantigen, ZnT8 -- a recently discovered fourth antigenic specificity recognized by an antibody in human blood that will help more accurately predict who is predisposed to type 1 diabetes. The initial research and discovery was led by Dr. Hutton and his research team at the Barbara Davis Center, and supported by the Childhood Diabetes Foundation in Denver.

A clinical trial will be conducted in children with extreme risk of developing type 1 diabetes using an insulin-based vaccination procedure aimed at preventing the occurrence of autoimmunity that inevitably leads to diabetes. A second trial is planned in the future based on ZnT8 and will develop similar prevention strategies.


Contact: Leslie Schwartz
Juvenile Diabetes Research Foundation International

Related medicine news :

1. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
2. Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
3. MM2 Group Establishes New Venture for Sofgel Manufacture in China
4. Sens. Kerry, Boxer and Feinstein call on FDA to Establish Maximum Level for Lead in Lipstick
5. CIG Corp. Establishes a Medical Advisory Board
6. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
7. Parascript Enters Medical Imaging Breast Cancer Detection Market With Established Image Analysis Technology
8. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
9. Nastech to Establish Subsidiary, MDRNA, Inc., as an Independent Company to Focus on the Development of RNA-Based Therapeutics
10. Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service
11. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
Post Your Comments:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology: